TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?

The Motley Fool Logo The Motley Fool By Geoffrey Seiler
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?

Hims & Hers reported strong Q3 results with 49% year-over-year revenue growth, reaching $599 million. The company is expanding its personalized treatment plans and discussing potential collaboration with Novo Nordisk for Wegovy injections.

Insights
GME   neutral

Mentioned as a comparative example of a previous meme stock rally


HIMS   positive

Strong revenue growth of 49%, increased subscriber base by 21%, 80% growth in personalized subscription customers, and attractive valuation metrics